JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

AI IN HEALTHCARE: USING CUTTING-EDGE TECHNOLOGIES TO REVOLUTIONIZE VACCINE DEVELOPMENT AND DISTRIBUTION

Nasrullah Abbasi[1], Nizamullah FNU[2], Shah Zeb[3]

[1, 2. 3]University: Washington University of Science and Technology, 2900 Eisenhower Ave, Alexandria, VA

[1]nabbasi.student@wust.edu, [2]Nizamullah.student@wust.edu, [3]szeb.student@wust.edu

Abstract: The field of vaccine development is being revolutionized by artificial intelligence (AI), which is bringing revolutionary advancements to every stage of the process from discovery to dissemination. This review focuses on a few important aspects as it examines how AI technology improve vaccine development procedures. By locating antigen targets, forecasting immune responses, and refining vaccine designs via sophisticated machine learning and computational biology, artificial intelligence (AI) expedites the search for new vaccines. Artificial Intelligence (AI) enhances clinical trial efficacy by facilitating real-time data monitoring, optimizing trial designs, and improving participant recruitment. AI improves quality control, predictive maintenance, and process efficiency in the production of vaccines, resulting in constant and dependable output. AI also facilitates timely and equitable vaccination delivery by optimizing cold chain management, transportation logistics, and supply chain management. Despite these developments, there are still issues with data integration and quality, model transparency, ethical and legal issues, and computational resource requirements when using AI in vaccine development. Prospective avenues for investigation comprise investigating tailored vaccinations, improving real-time monitoring, and advocating for worldwide health parity. Leveraging AI's full potential to advance vaccine research will require addressing these issues and seeking creative solutions. Improvements in health outcomes and more efficient responses to risks to global health will result from the ongoing cooperation of AI specialists, vaccine developers, and public health agencies.

Key words: AI, machine learning, clinical trials, supply chain management, cold chain management, manufacturing, quality assurance, distribution, supply chain management, supply chain integration, ethical issues, customized vaccinations, real-time monitoring, and global health equality.

INTRODUCTION

In several industries, including healthcare, artificial intelligence (AI) is becoming acknowledged as a game-changer. AI's incorporation into healthcare systems holds the potential to completely transform not just how we diagnose and treat illnesses, but also how the entire healthcare delivery system is run [1]. The fundamentals of AI in healthcare, it's possible uses, and its significant influence on the sector are all covered in this brief. Artificial Intelligence (AI) is the simulation of human intelligence in devices that are made to think and learn like people. This includes a range of technologies that allow robots to do tasks that traditionally require human intellect, such as computer vision, natural language processing, and machine learning (ML). Artificial intelligence (AI) is utilized in the healthcare industry to improve decision-making processes, forecast outcomes, and analyze complicated medical data [2].

Evolution and Historical Context: Artificial Intelligence in healthcare is not a brand-new idea. Early AI applications included straightforward rule-based systems for assistance in diagnosis. But as more advanced algorithms and processing capacity have become available, AI's function has grown dramatically [3]. AI systems of today are capable of processing enormous volumes of data at previously unheard-of rates, providing previously unachievable insights and forecasts [4].

There are various phases in the development of AI in healthcare:

- Early expert systems were designed for specialized diagnostic tasks and relied on pre-established criteria.

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

- Advances in pattern identification and predictive modeling resulted from a change in attention towards algorithms that could learn from data.
- AI systems are now able to process and interpret complex data, such as text, photos, and genetic material, thanks to the advancement of neural networks and deep learning techniques.

AI'S CURRENT USES IN HEALTHCARE

The uses of AI in healthcare are numerous and growing.

- **Diagnostic Support:** AI systems are highly accurate at analyzing medical pictures, including MRIs, CT scans, and X-rays. For example, AI algorithms are frequently more efficient than human radiologists in specific jobs, such as detecting early indicators of diseases like cancer [5].
- **Predictive analytics:** AI algorithms are able to forecast patient outcomes, including the chance of recurring illnesses or the possibility of developing certain disorders. These forecasts aid in the development of individualized treatment programs and enhance patient care [6].
- **Drug Discovery:** AI finds possible drug candidates by evaluating complex biological data, which speeds up the drug discovery process. This shortens the time and expense involved in introducing novel medications to the market [7].
- **Personalized medicine:** AI enables the customization of treatment regimens based on unique patient data, such as genetic makeup, lifestyle choices, and past medical records, resulting in more focused and efficient treatments [8].
- **Operational Efficiency:** AI improves patient flow management, scheduling, and resource allocation in hospitals. This lowers expenses while increasing overall efficiency [9].

OBSTACLES AND THINGS TO THINK ABOUT

Even if AI has a lot of potential, there are a few issues that need to be resolved:

- **Data security and privacy:** To avoid breaches and misuse, handling sensitive health data necessitates strong security measures.
- **Fairness and Bias:** AI systems may unintentionally reinforce preexisting biases in medical data, which could result in inequities in patient care. It is imperative to guarantee equity and fairness in AI applications [10].
- **Integration with Current Systems:** It can be difficult and requires careful planning to integrate AI technology with the workflows and systems used in the healthcare industry today.

Healthcare AI's Future: AI in healthcare has a bright future. AI's capabilities will continue to be enhanced by increasing datasets, better algorithms, and ongoing technological developments. The application of AI in telemedicine, genomics, and remote monitoring are examples of emerging trends. AI systems will become more important as they develop in terms of changing the way healthcare is delivered, enhancing patient outcomes, and spurring advancements in medical research [11]. AI has the potential to completely transform healthcare by increasing operational effectiveness, personalizing care, and boosting diagnostic accuracy. As technology develops further, its incorporation into healthcare systems will surely result in important breakthroughs and improved patient care in general [12].

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

THE USE OF AI IN THE DEVELOPMENT OF VACCINES

One of the most important aspects of public health is the development of vaccinations, which has a big influence on managing and preventing disease. Even though they work, traditional vaccine development procedures are frequently expensive, time-consuming, and resource-intensive. In this area, artificial intelligence (AI) has come to light as a game-changer, providing creative solutions that improve the accuracy, speed, and efficiency of vaccine production. This brief examines the main uses of AI, how it is changing the field of vaccine creation, and how this will affect vaccine research in the future [13].

Interruption of Vaccine Research: Accelerating the identification of viable vaccine candidates is one of the main ways AI is revolutionizing the vaccine development process. Large-scale biological data can be analyzed by AI algorithms, especially those that use deep learning and machine learning, to find potential targets for vaccine development. Conventional techniques frequently entail protracted trial-and-error procedures, while AI is able to quickly sort through data and identify candidates with great promise [14]. AI, for example, is capable of identifying proteins that are likely to elicit a robust immune response by analyzing the genetic sequences of pathogens. Researchers may prioritize specific targets and create vaccines with a higher chance of success thanks to this data-driven method. When it came to quickly selecting vaccine targets in the context of newly developing infectious diseases like the COVID-19 pandemic, artificial intelligence was instrumental.

Improving Clinical and Preclinical Research: Artificial Intelligence has an impact on preclinical and clinical trials in addition to the discovery stage. AI-powered models can quantify the effectiveness of various vaccine formulations, forecast possible adverse effects, and simulate how a vaccination will interact with the immune system [15]. In the end, this predictive ability expedites the process by assisting in the design of more focused and efficient clinical studies AI technologies are employed in clinical trials to track patient data and provide real-time analysis of results. By spotting trends and abnormalities in trial data, machine learning algorithms can enhance early detection of side effects and optimize dosage schedules. AI can also be used to stratify patients according to how likely they are to respond to a vaccine, resulting in more individualized and efficient treatment plans [16].

Vaccine Formulation Optimization: AI is crucial to the optimization of vaccine formulation as well. Choosing the appropriate antigens, adjuvants (substances that strengthen the immune response), and delivery methods is a crucial step in the development of a vaccine. AI systems are capable of analyzing different formulation factors and forecasting the best possible combinations. By using this method, fewer experimental trials are required, which saves time and money. AI is capable of modeling, for instance, the effects of various adjuvants on the immune response and recommending the best possible compositions to enhance effectiveness while reducing negative effects [17]. The development of vaccinations that are safe and efficacious enough for general usage is aided by this data-driven optimization.

Simplifying Production Procedures: The next difficulty after testing and identification of a vaccine candidate is to scale up production. Artificial Intelligence facilitates the optimization of vaccine manufacturing processes by enhancing production line efficiency and quality control. Real-time production monitoring, deviation detection, and adjustment making are all possible with AI-driven systems, which also guarantee constant product quality [18]. Artificial intelligence also plays a role in predictive maintenance. Artificial Intelligence can forecast when machinery is likely to break down or need maintenance by examining data from manufacturing equipment. This proactive strategy guarantees continuous production and minimizes downtime, which is essential for fulfilling the enormous demand for vaccinations, particularly during pandemics [19].

Encouraging the Distribution of Vaccines: Artificial Intelligence has a role in vaccine development that goes beyond research and manufacturing to include dissemination. Supply chain logistics can be optimized by AI systems, guaranteeing a fair and effective distribution of vaccines. Machine learning algorithms are capable of managing inventories, predicting demand in various places, and optimizing transportation routes. AI was used, for example, to forecast the areas where

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

vaccines would be most urgently needed during the COVID-19 epidemic and to adjust distribution plans appropriately [20]. Delays are minimized and vaccinations are distributed to the populations that require them the most thanks to this improvement.

Obstacles and Prospects for the Future: The application of AI to vaccine development is fraught with difficulties, despite its promise. The availability and quality of data are crucial because AI systems need big, high-quality datasets in order to provide precise predictions. Gaining trust and streamlining regulatory approvals also depend on AI models being clear and comprehensible. In the future, AI's contribution to vaccine development is probably going to increase even more. Processes for developing vaccines will continue to be improved by increases in processing power and AI algorithms [21]. Future developments could include even more individualized vaccinations, quicker reactions to newly discovered infections, and more effective mechanisms for manufacturing and delivery. Artificial intelligence (AI) is transforming the development of vaccines by speeding up discovery, refining formulations, boosting trial procedures, and strengthening production and dissemination [22]. As AI technologies advance, their incorporation into vaccine production will result in speedier responses to health emergencies, more potent vaccinations, and general gains in public health outcomes.

AI-POWERED ADVANCES IN THE SEARCH FOR VACCINES

The process of finding a vaccine is difficult, and it frequently takes years of study and significant funding before a promising candidate is identified [23]. But with the emergence of artificial intelligence (AI), revolutionary breakthroughs that greatly improve and speed up this process have been made possible. Researchers may now navigate the complex terrain of vaccine discovery with previously unheard-of efficiency and precision by utilizing cutting-edge AI technologies. This synopsis explores the ways artificial intelligence (AI) is transforming the field of vaccine discovery, the major advancements it delivers, and the consequences for future vaccine research [24].

Recognizing AI in the Development of Vaccines: Artificial Intelligence (AI) is the umbrella term for a set of technologies that allow robots to mimic human cognition through data analysis and learning. Machine learning (ML), deep learning, and computational biology are the main AI tools used in vaccine discovery. These tools allow researchers to evaluate large datasets and find viable candidates for vaccines [25]. Large volumes of complex biological data can be handled and interpreted by these technologies, speeding up the discovery process and revealing fresh insights that conventional methods could miss.

Determining the Antigen Targets: The identification of appropriate antigen targets—particular components of pathogens that can elicit an immune response—is one of the essential phases in the development of vaccines. It can take a lot of time and work to identify these targets using traditional methods. AI transforms this procedure by analyzing pathogen genetic and proteomic data utilizing algorithms [26]. The genomic sequences of bacteria or viruses can be analyzed by machine learning algorithms to find proteins or other molecular structures that are likely to trigger a robust immune response. For instance, AI played a key role in swiftly determining that the SARS-CoV-2 virus's spike protein was a promising candidate for vaccine development during the COVID-19 epidemic. AI algorithms can expedite the process of choosing potential vaccine candidates by predicting which regions of the pathogen's proteins are most likely to function as antigens [27].

Anticipating Immune Reactions: AI is also capable of forecasting the interactions between several vaccination candidates and the immune system. Based on biological principles and historical data, deep learning models can mimic the ways in which different antigens would elicit immune responses. Before being put through laboratory testing, these models can offer insights into the possible efficacy of certain vaccine compositions [28]. AI is also capable of analyzing preclinical study data to forecast a vaccine's performance in human trials. AI algorithms assess immune response patterns and adverse effect profiles from prior research to forecast the chance of novel vaccination candidates to be successful. By assisting in the prioritization of candidates for clinical trials, this predictive power may help lower the number of unsuccessful trials and speed up the entire process [29].

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

Improving the Design of Vaccinations: Optimizing antigens, adjuvants—substances that boost the immune response—and delivery mechanisms are all important steps in the creation of a vaccine that works. AI is essential to this optimization process because it can analyze the effects of various combinations of these components on the immune response [30]. AI algorithms, for example, can simulate the ways in which various adjuvants increase the potency of particular antigens. Artificial intelligence (AI) can recommend the best formulations that optimize the immune response while avoiding negative effects by reviewing data from earlier studies and simulations. The creation of efficient vaccinations is sped up by this data-driven strategy, which also lowers the number of experimental trials required [31].

Combining Omits Information: Large volumes of data are produced by omics technologies including proteomics, metabolomics, and genomes, which are essential for the development of vaccines. AI is skilled at combining and examining these many datasets to find fresh information. AI, for instance, can more precisely identify possible vaccine targets by fusing proteomic data from human immune responses with genetic data from pathogens [32]. Artificial Intelligence can offer a comprehensive perspective on the interactions between viruses and the host immune system by integrating data from many omics layers. By using a comprehensive approach, we can better understand the mechanisms underlying disease and use that knowledge to build vaccines that are more likely to be successful against certain strains or variants [33].

Taking on the Issues and Looking Ahead: The use of artificial intelligence (AI) in vaccine research is fraught with difficulties, despite its revolutionary potential. The success of AI models depends heavily on the quantity and quality of the data. Achieving accurate predictions requires making sure the data used to train algorithms is complete and representative. In order to win over researchers and regulatory agencies, AI models need to be clear and easy to understand. Validating and certifying novel vaccine candidates will depend on the development of models that offer concise explanations for their predictions as AI technologies progress. It is anticipated that AI will play a bigger part in vaccine development in the future [34]. More processing capacity, improved AI algorithms, and the incorporation of a wider range of data sources will all contribute to the efficiency and precision of vaccine discovery. AI is probably going to keep speeding up the process of finding novel vaccine targets, improving vaccine designs, and ultimately helping us respond to emerging infectious illnesses more quickly and effectively [35]. To sum up, artificial intelligence (AI) is transforming the field of vaccine discovery through its ability to enhance the identification of antigen targets, forecast immune responses, optimize vaccine designs, and integrate intricate omits data. AI technology will become more and more important in vaccine research and development as it develops, resulting in quicker and more efficient responses to the world's health problems [36].

AI'S IMPACT ACROSS VARIOUS FIELDS

Artificial Intelligence (AI) is transforming multiple fields by offering innovative solutions and efficiencies. In healthcare, AI aids in diagnosing diseases and personalizing treatments. In finance, it enhances fraud detection and risk management. The automotive industry benefits from AI through advancements in autonomous driving and predictive maintenance. In agriculture, AI optimizes crop management and pest control.



Figure: 1 AI impact across different fields

AI-ASSISTED CLINICAL TRIAL ACCELERATION

A vital component of vaccine development, clinical trials ascertain the safety and effectiveness of novel vaccinations prior to their approval for general distribution. Clinical trial execution is traditionally a costly and time-consuming procedure that takes years to complete and requires significant resources. In this field, artificial intelligence (AI) has become a disruptive force, providing creative ways to expedite and simplify clinical studies [37]. This short examines the applications, advantages, and difficulties of artificial intelligence in transforming the clinical trial process.

Improving Patient Enrollment and Recruitment: The recruitment and enrollment of volunteers who fulfill particular criteria is one of the main issues in clinical studies. Conventional techniques for determining who qualifies can be time-consuming and labor-intensive. In order to more effectively identify possible candidates, AI analyzes electronic health records (EHRs) and other medical data AI systems are capable of sorting through massive amounts of patient data to match patients with the needs of clinical trials [38]. Examining genetic data, medical history, and present health issues are all part of this procedure. AI ensures that clinical trials be started more quickly and with the proper participants, cutting down on delays and shortening the entire timeframe. It does this by increasing the accuracy and speed of patient recruitment [39].

Improving Protocols and Trial Design: AI can greatly improve clinical trial design by streamlining procedures and protocols. In order to spot trends and forecast results, machine learning algorithms can evaluate past trial data, which enables researchers to create more successful and productive

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

experiments [40]. For instance, by examining data from earlier research, AI can assist in determining the ideal dosage, frequency, and length of treatment. On the basis of predictive models, it can also help choose relevant endpoints and outcome measurements. Trials can be designed more effectively to minimize failure risk and achieve significant outcomes thanks to this data-driven approach [41].

Real-time Data Monitoring and Analysis: Artificial Intelligence (AI) enables more dynamic and responsive trial administration by facilitating real-time data monitoring and analysis during clinical trials. AI-driven solutions are able to track participant data in real time, including reported side effects, physiological measurements, and lab results. Real-time data can be analyzed by machine learning algorithms to find patterns and anomalies that enable the early detection of possible problems or unfavorable occurrences [42]. This feature allows for timely interventions and procedure modifications to improve participant safety. Furthermore, real-time data analysis facilitates a quicker evaluation of the vaccine's efficacy, which may result in quicker judgments and decisions.

Customizing the Dosage and Treatment: Clinical trials are one setting where AI's ability to customize care is especially important. The goal of personalized medicine is to customize care based on unique patient traits, including underlying medical issues, lifestyle choices, and genetic makeup. This strategy is made easier by AI, which analyzes patient data to identify the best treatment plans for various subgroups. AI can assist in determining which people in vaccine studies are most likely to benefit from particular formulations or dosages [43]. Because the vaccination is tailored to a variety of patient demographics, this personalized approach not only increases the likelihood that the trial will be successful, but it also increases the vaccine's overall effectiveness.

Simplifying the Process of Regulatory Compliance: Clinical trial regulatory compliance is a crucial component. By automating the reporting and documentation procedures demanded by regulatory bodies, AI can help in this domain. Artificial intelligence (AI) systems are capable of producing detailed reports, monitoring trial protocol compliance, and making sure that all required paperwork is correctly kept up to date. AI lowers the administrative load on trial teams and lowers the possibility of mistakes or omissions by automating these processes [44]. Smoother interactions with regulatory organizations are made possible by the streamlining of regulatory processes, which helps guarantee that trials are carried out in compliance with legal and ethical standards.

Obstacles and Prospects for the Future: The application of AI in clinical trials has certain drawbacks despite its many advantages. Since AI models rely on accurate and representative datasets, it is imperative to ensure the quality and integrity of data. Security and privacy of data are also crucial factors, particularly when managing sensitive health data [45]. Even though AI can increase productivity, human oversight must be maintained throughout the clinical trial process. Artificial intelligence (AI) techniques should be employed in conjunction with human judgment, not as a substitute for it. Gaining trust and getting the results you want depend on AI models being transparent and comprehensible [46].

It is anticipated that AI will play an increasingly larger part in clinical studies in the future. Improvements in trial design, patient recruiting, and data analysis will continue to be fueled by advances in AI technology and easier access to a wider range of datasets. The use of AI in clinical trials will help create vaccines more quickly and efficiently as it advances, which will ultimately lead to better public health outcomes [47]. Artificial intelligence is speeding up clinical trials through improving patient recruiting, trial design optimization, real-time data monitoring, adverse event prediction, therapy personalization, and regulatory compliance simplification. The application of AI technology in clinical trials will spur additional advancements and efficiency as the field grows, resulting in the development of vaccines more quickly and successfully [48].

JURIHUM
Jurnal Inovasi dan Humaniora

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

AI IN THE PRODUCTION AND QUALITY CONTROL OF VACCINES

A crucial stage in the development and dissemination of vaccines is manufacturing, which calls for exacting procedures and stringent quality control to guarantee consistency, safety, and efficacy. Conventional vaccine production is labor- and resource-intensive, frequently requiring many steps and close supervision. In this field, artificial intelligence (AI) has become a game-changer, providing creative ways to improve accuracy, dependability, and efficiency. This short examines the applications, advantages, and difficulties of artificial intelligence in the manufacturing and quality control of vaccines [49].

Increasing Production Effectiveness: Artificial Intelligence plays a major role in increasing the manufacturing processes' efficiency for vaccines. The synthesis of antigens, their purification, formulation, and filling are some of the crucial steps in the vaccination process. To guarantee that the finished product satisfies regulatory requirements, each step needs to be carefully managed. Massive volumes of manufacturing data can be analyzed by AI-driven systems to find areas for improvement and optimize these operations. Machine learning algorithms, for instance, are capable of real-time monitoring and management of production variables including temperature, pH levels, and flow rates [50]. This capacity lowers unpredictability and guarantees constant product quality by assisting in the maintenance of ideal conditions throughout the manufacturing process. AI can improve process automation by precisely controlling machinery and equipment. Artificial intelligence (AI)-powered automated systems are capable of managing and moving materials, lowering the possibility of human error, and boosting total production throughput more effectively than human operators.

Enhancing Process Optimization: The production of vaccines is a complex process that frequently calls for precise adjustments to achieve the best possible outcomes. AI is excellent at streamlining these procedures by examining past data and seeing trends that human analysis would overlook [51]. To find the best circumstances for antigen expression or purification, for example, AI algorithms can examine data from earlier manufacturing runs. Artificial intelligence (AI) systems can make real-time modifications to increase yield and save costs by continuously learning from this data. More exact control over the production process is made possible by this data-driven approach, which results in better vaccines and more economical use of resources [52].

Maintaining Quality Assurance: A crucial component of vaccine production is quality control, which guarantees that every batch of vaccine satisfies stringent safety and efficacy requirements. AI improves quality control by identifying deviations from set norms and automating the monitoring of quality measurements. Real-time product sample examination, such as visual inspections, chemical assays, and biological testing, can be carried out by AI-powered systems [53]. For example, computer vision algorithms are able to identify packaging flaws or particulate contamination that human inspectors would overlook. In order to detect possible problems and anticipate when a batch might fail, machine learning models can evaluate data from a variety of quality control tests. This enables prompt responses.

AI can help to ensure uniformity between batches of production. Artificial intelligence (AI) systems are able to recognize and rectify variations that could affect the quality of the final product by analyzing data from various sources, including raw materials and production circumstances. By being proactive, we can make sure that every batch of vaccination satisfies the strictest requirements for efficacy and safety [54].

Improving Predictive Upkeep: Maintaining manufacturing equipment and avoiding unplanned downtime need predictive maintenance. By evaluating data from equipment sensors to forecast when maintenance is required, artificial intelligence (AI) helps in predictive maintenance. When analyzing sensor data, including vibration, temperature, and pressure, machine learning algorithms can identify trends that indicate when equipment is likely to need maintenance or repair. Artificial Intelligence helps avoid production disruptions and lowers the chance of final product faults by seeing possible problems before they result in equipment failures [55]. By reducing unscheduled downtime and

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

guaranteeing that production schedules are met, this method not only increases the overall efficiency of manufacturing equipment but also improves its reliability.

Obstacles and Things to Think About: Even though AI has several advantages for quality assurance and vaccine production, there are still some issues that need to be resolved. Making sure AI systems are dependable and of high quality is one of the main obstacles. Since AI models can only be as good as the data they are trained on, biased or low-quality data sets can produce predictions and choices that are not correct [56]. Privacy and data security are also crucial factors to take into account, especially when managing sensitive data pertaining to the manufacturing of vaccines. Ensuring regulatory compliance and putting strong cybersecurity measures into place are crucial for safeguarding data and preserving public confidence in AI systems. Meticulous planning and coordination are needed to integrate AI into the current production processes. It include personnel training, infrastructure updates, and making sure AI systems integrate seamlessly with current procedures and technologies [57].

Prospective Courses: AI has a bright future in quality assurance and vaccine production. Sustained progress in artificial intelligence technology, such as enhanced machine learning algorithms and data analytics capabilities, will augment the efficacy and accuracy of vaccine manufacturing. It is anticipated that artificial intelligence would play a bigger part in more sophisticated applications like customized vaccinations and cutting-edge bio manufacturing methods, in addition to conventional manufacturing processes [58]. AI's continued development will spur advances in vaccine production that will raise product quality, lower costs, and hasten vaccination availability for people throughout the world. To sum up, artificial intelligence is transforming the production of vaccines and quality assurance through increased productivity, process optimization, quality assurance, and predictive maintenance. Improvements in safety, efficacy, and overall manufacturing efficiency will be driven by the continued advancement of AI technologies in vaccine production, which will eventually enhance public health outcomes and speed up the response to emerging illnesses [59].

USING AI TO IMPROVE THE DISTRIBUTION OF VACCINES

Assuring that vaccines are provided effectively and fairly to people in need, vaccination distribution is a crucial aspect of public health. Complicated logistics are involved in the typical vaccine distribution process, including as inventory management, storage, and shipping. These can be difficult to handle, particularly in times of medical emergency. In terms of vaccine distribution optimization, artificial intelligence (AI) has become a game-changer, providing creative ways to improve responsiveness, accuracy, and efficiency [60]. This article examines the applications, advantages, and difficulties of AI in transforming the delivery of vaccines.

Simplifying the Management of the Supply Chain: AI is essential for vaccine supply chain management optimization because it increases the efficacy and efficiency of every phase of the distribution process. There are several processes in the vaccine supply chain, from preparation and packing to delivery and transportation [61]. By offering real-time insights and predictive analytics to efficiently manage each phase, AI technology can improve this process. In order to predict demand and improve inventory levels, machine learning algorithms examine both historical data and the present environment. Artificial intelligence (AI) aids in more precise stock level management by anticipating which areas will require vaccinations and in what amounts. This helps to avoid shortages or surpluses. By ensuring vaccines are available where they are most needed, this predictive capability lowers waste and boosts overall distribution efficiency [62].

Streamlining Logistics and Transportation: A crucial part of vaccine distribution is transportation, which calls for meticulous planning to guarantee that shots are delivered in the best possible circumstances and arrive at their destinations on schedule. Artificial intelligence (AI) technologies improve logistics and transportation by streamlining scheduling, routing, and real-time monitoring. In order to identify the most effective transportation routes, AI-powered route optimization algorithms examine data such as traffic patterns, meteorological conditions, and delivery windows [63]. This feature ensures that vaccines are kept within the necessary temperature ranges and reach at immunization sites on time by cutting down on delivery times and delays. In

JURIHUM
Jurnal Inovasi dan Humaniora

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

order to guarantee that vaccinations are stored and transported under the right circumstances, AI systems may also track variables like temperature and humidity in real-time. This real-time monitoring aids in preventing temperature swings that can jeopardize the effectiveness of vaccines [64].

Improving Cold Chain Dispatch: Strict cold chain management is necessary for many vaccinations in order to preserve their effectiveness from the point of production until administration [65]. By offering real-time data and predictive analytics to guarantee that vaccines are carried and kept within the necessary temperature ranges, artificial intelligence (AI) technologies play a major role in cold chain management. Throughout the cold chain, artificial intelligence (AI) systems can continuously monitor temperature and humidity levels, warning stakeholders of any deviations from the ideal circumstances. Additionally, predictive models can foresee future problems like equipment malfunctions or power outages, enabling proactive measures to stop vaccine deterioration [66].

Enhancing Inventories Administration: The timely and appropriate availability of vaccines depends on efficient inventory management. Artificial intelligence (AI) improves inventory management by giving real-time visibility into stock levels and forecasting future demands using historical trends and current data. Artificial intelligence (AI)-powered inventory management systems can forecast future demand and analyze consumption trends to automate the replenishment process. This feature assists in preventing overstocking, minimizing stock outs, and maintaining ideal inventory levels [57]. Additionally, supply chain employees can concentrate on more strategic duties as a result of automated inventory management, which lessens their administrative workload.

Encouraging Fair Distribution: Distributing vaccines equitably is an important objective, especially in times of public health emergency. By evaluating demographic and geographic data, AI can help achieve this aim by identifying high-risk or neglected communities who need priority access to vaccinations. In order to establish distribution priorities, AI algorithms can evaluate variables like disease prevalence, population density, and socioeconomic circumstances [69]. By ensuring that vaccines are distributed equitably and reach the groups that need them the most, this data-driven strategy helps promote more equitable health outcomes.

PROSPECTIVE COURSES

Anticipating the future, the following avenues can improve the influence of AI on vaccine development:

- .AI has the ability to propel the creation of vaccines that are specifically matched to each patient's genetic makeup and medical needs. More accurate and efficient immunization programs may be made possible by developments in AI and genomics.
- AI can be utilized for real-time post-marketing surveillance of vaccine safety and efficacy. Real-time data monitoring and analysis can yield insightful information and speed up reaction times to new problems.
- By maximizing vaccination distribution plans and guaranteeing that vaccines reach underprivileged groups, AI can help advance global health equity. Global access to and equitable distribution of vaccines can be facilitated by AI-driven analytics.
- In order to address global health concerns, it will be essential to strengthen collaboration between public health agencies, vaccine developers, and AI researchers. Collaborative efforts have the potential to stimulate innovation and guarantee the successful integration of AI technologies into vaccine development procedures.

Taking on the Issues and Looking Ahead: Even though AI has several advantages for optimizing vaccine distribution, there are a few issues that need to be resolved. Integration and high-quality data are essential to AI systems' performance. Making good forecasts and judgments requires ensuring that data from several sources is thorough, accurate, and compatible. Additionally crucial factors to take into account are data security and privacy, especially when managing private medical and logistical data. Ensuring data security and upholding regulatory compliance are essential for preserving public confidence in artificial intelligence (AI) technologies [71]. Considerable planning

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

and coordination are needed for the integration of AI into the current distribution systems. It include personnel training, infrastructure updates, and making sure AI technologies integrate seamlessly with current systems and procedures.

Obstacles and Prospects for AI-Powered Vaccine Research

The creation of vaccines has undergone several revolutions due to artificial intelligence (AI), ranging from discovery and clinical trials to manufacturing and distribution. While AI offers revolutionary potential, there are a number of obstacles that must be overcome before it can be fully integrated into the creation of vaccines [72]. Maximizing the potential of AI in this industry requires addressing these issues and figuring out future approaches. This short examines the main obstacles to AI-driven vaccine development and suggests future paths to get around them [73].

Combining AI with Conventional Approaches: Although AI provides strong tools for vaccine research, a comprehensive strategy must incorporate AI with conventional techniques and knowledge. AI should supplement current knowledge and techniques, not replace them. Encouraging multidisciplinary cooperation amongst biologists, doctors, public health experts, and AI specialists can guarantee that AI tools are employed efficiently and in tandem with conventional methods [74]. The amalgamation of AI and conventional approaches facilitates a more all-encompassing strategy for vaccine development.

CONCLUSION

By improving several phases from discovery to distribution, the incorporation of Artificial Intelligence (AI) into vaccine production has dramatically changed the public health environment. AI's use in vaccine development has many benefits, such as expedited vaccine candidate discovery, better clinical trial outcomes, enhanced production procedures, and effective distribution networks. Through the utilization of cutting-edge artificial intelligence technology, scholars and public health experts can effectively and efficiently tackle intricate problems. AI-driven advances in vaccine development have simplified the process of determining antigen targets, forecasting immunological reactions, and refining vaccination formulations. Better and faster discovery procedures have been made possible by machine learning and computational biology, which has resulted in the development of potential vaccine candidates.

AI has streamlined trial designs, expedited participant recruitment and enrollment, and allowed for real-time data monitoring in clinical studies. The efficiency of clinical trials has increased thanks to predictive models and automation, which has decreased the time and cost needed to get vaccines to the market. The safety and efficacy of vaccine trials are further guaranteed by AI's capacity to anticipate and control unfavorable outcomes. AI has also completely changed the production of vaccines and quality assurance by facilitating predictive maintenance, increasing process efficiency, and strengthening quality control procedures. The production of vaccinations has become more consistent and reliable thanks to automated technologies and real-time monitoring, which guarantees that the shots fulfill strict safety and efficacy requirements.

AI has improved cold chain management, logistics of transportation, and supply chain management in the distribution of vaccines. Artificial Intelligence (AI) has improved vaccine distribution efficiency and efficacy by anticipating demand, planning routes, and guaranteeing optimal storage conditions. This has led to more equitable access and prompt delivery. Even with these developments, a number of obstacles still exist. Critical aspects that need attention include managing computational resources, handling ethical and regulatory considerations, ensuring data quality and integration, and addressing model transparency and interpretability. Overcoming these obstacles and keeping an eye out for fresh opportunities like tailored vaccinations, real-time surveillance, and global health equity are critical to the future of AI in vaccine development.

AI technologies will probably play a bigger part in vaccine research as they advance, spurring more advancements and advancements in public health. Researchers and public health professionals can continue to progress vaccine development, which will ultimately lead to better health outcomes and more effective responses to global health concerns, by tackling current problems and utilizing AI to its fullest potential. In order to influence vaccine creation going forward and guarantee that AI makes

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

a good contribution to advancements in global health, it will be crucial for AI specialists, vaccine developers, and public health organizations to maintain their ongoing collaboration.

REFERENCES

1. Bormann C, Kanakasabapathy M, Thirumalaraju P, Dimitriadis I, Souter I, Hammer K, et al., editors. Development of an artificial intelligence embryo witnessing system to accurately track and identify patient specific embryos in a human IVF laboratory. HUMAN REPRODUCTION; 2021: OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND.
2. Bormann CL, Curchoe CL, Thirumalaraju P, Kanakasabapathy MK, Gupta R, Pooniwala R, et al. Deep learning early warning system for embryo culture conditions and embryologist performance in the ART laboratory. Journal of Assisted Reproduction and Genetics. 2021; 38(7):1641-6.
3. Kanakasabapathy MK, Thirumalaraju P, Kandula H, Doshi F, Sivakumar AD, Kartik D, et al. Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images. Nature Biomedical Engineering. 2021; 5(6):571-85.
4. Curchoe CL, Malmsten J, Bormann C, Shafiee H, Farias AF-S, Mendizabal G, et al. Predictive modeling in reproductive medicine: Where will the future of artificial intelligence research take us? Fertility and sterility. 2020; 114(5):934-40.
5. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015; 349(6245):255-60.
6. Mahesh B. Machine Learning Algorithms-A Review. International Journal of Science and Research (IJSR) [Internet]. 2020; 9:381-6.
7. Bao X, Bergman L, Thompson R, editors. Stacking recommendation engines with additional meta-features. Proceedings of the third ACM conference on Recommender systems; 2009.
8. Indurkhya N, Damerau FJ. Handbook of natural language processing: CRC Press; 2010.
9. Grys BT, Lo DS, Sahin N, Kraus OZ, Morris Q, Boone C, et al. Machine learning and computer vision approaches for phenotypic profiling. Journal of Cell Biology. 2017; 216(1):65-71.
10. Deng L, Li X. Machine learning paradigms for speech recognition: An overview. IEEE Transactions on Audio, Speech, and Language Processing. 2013; 21(5):1060-89.
11. Wang S, Chaovalitwongse W, Babuska R. Machine learning algorithms in bipedal robot control. IEEE Transactions on Systems, Man, and Cybernetics, Part C (Applications and Reviews). 2012; 42(5):728-43.
12. Gangavarapu T, Jaidhar C, Chanduka B. Applicability of machine 44 learning in spam and phishing email filtering: review and approaches. Artificial Intelligence Review. 2020; 53(7).
13. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. New England Journal of Medicine. 2019; 380(14):1347-58.
14. Deo RC. Machine learning in medicine. Circulation. 2015; 132(20):1920- 30.
15. Sahoo D, Swanson L, Sayed IM, Katkar GD, Ibeawuchi S-R, Mittal Y, et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nature communications. 2021; 12(1):1- 14.
16. Wang Y, Seo B, Wang B, Zamel N, Jiao K, Adroher XC. Fundamentals, materials, and machine learning of polymer electrolyte membrane fuel cell technology. Energy and AI. 2020:100014. 46. Singh A, Thakur N, Sharma A, editors. A review of supervised machine learning algorithms. 2016 3rd International Conference on Computing for Sustainable Global Development (INDIACom); 2016: Ieee.
17. Lloyd S, Mohseni M, Rebentrost P. Quantum algorithms for supervised and unsupervised machine learning. arXiv preprint arXiv:13070411. 2013.

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

18. Adorf CS, Moore TC, Melle YJ, Glotzer SC. Analysis of self-assembly pathways with unsupervised machine learning algorithms. The Journal of Physical Chemistry B. 2019; 124(1):69-78.
19. Huang G, Song S, Gupta JN, Wu C. Semi-supervised and unsupervised extreme learning machines. IEEE transactions on cybernetics. 2014; 44(12):2405-17.
20. Zhu X, Goldberg AB. Introduction to semi-supervised learning. Synthesis lectures on artificial intelligence and machine learning. 2009; 3(1):1-130.
21. Oliver A, Odena A, Raffel C, Cubuk ED, Goodfellow IJ. Realistic evaluation of deep semi-supervised learning algorithms. arXiv preprint arXiv:180409170. 2018.
22. Patel N, Wang JT. Semi-supervised prediction of gene regulatory networks using machine learning algorithms. Journal of biosciences. 2015; 40(4):731-40.
23. Szepesvári C. Algorithms for reinforcement learning. Synthesis lectures on artificial intelligence and machine learning. 2010; 4(1):1-103.
24. Xu X, Zuo L, Huang Z. Reinforcement learning algorithms with function approximation: Recent advances and applications. Information Sciences. 2014; 261:1-31.
25. Zhou V. Machine Learning for Beginners: An Introduction to Neural Networks. Towards Data Science. 2019. 56. Deng L, Yu D. Deep learning: methods and applications. Foundations and trends in signal processing. 2014; 7(3–4):197-387.
26. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015; 521(7553):436-44. 58. Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug discovery today. 2017; 22(11):1680-5.
27. Ravì D, Wong C, Deligianni F, Berthelot M, Andreu-Perez J, Lo B, et al. Deep learning for health informatics. IEEE journal of biomedical and health informatics. 2016; 21(1):4-21.
28. Dargan S, Kumar M, Ayyagari MR, Kumar G. A survey of deep learning and its applications: a new paradigm to machine learning. Archives of Computational Methods in Engineering. 2020; 27(4):1071-92.
29. Robinson MC, Glen RC. Validating the validation: reanalyzing a largescale comparison of deep learning and machine learning models for bioactivity prediction. Journal of computer-aided molecular design. 2020:1- 14.
30. Ongsulee P, editor Artificial intelligence, machine learning and deep learning. 2017 15th International Conference on ICT and Knowledge Engineering (ICT&KE); 2017: IEEE
31. Omankwu OC, Nwagu CK, Inyiama H. Robotics and artificial 45 intelligence: Differences and similarities. International Journal of Computer Science and Information Security (IJCSIS). 2017; 15(12).
32. Krishnamoorthy C, Rajeev S. Artificial Intelligence and Expert Systems for Artificial Intelligence Engineers: CRC press; 2018
33. Yeung S, Downing NL, Fei-Fei L, Milstein A. Bedside computer visionmoving artificial intelligence from driver assistance to patient safety. N Engl J Med. 2018; 378(14):1271-3.
34. Khemasuwan D, Sorensen JS, Colt HG. Artificial intelligence in pulmonary medicine: computer vision, predictive model and COVID-19. European Respiratory Review. 2020; 29(157).
35. Findlay MR, Freitas DN, Mobed-Miremadi M, Wheeler KE. Machine learning provides predictive analysis into silver nanoparticle protein corona formation from physicochemical properties. Environmental Science: Nano. 2018; 5(1):64-71.
36. Papa E, Doucet J, Sangion A, Doucet-Panaye A. Investigation of the influence of protein corona composition on gold nanoparticle bioactivity using machine learning approaches. SAR and QSAR in Environmental Research. 2016; 27(7):521-38
37. Duan Y, Coreas R, Liu Y, Bitounis D, Zhang Z, Parviz D, et al. Prediction of protein corona on nanomaterials by machine learning using novel descriptors. NanoImpact. 2020; 17:100207.

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

38. Le TC, Penna M, Winkler DA, Yarovsky I. Quantitative design rules for protein-resistant surface coatings using machine learning. Scientific reports. 2019; 9(1):1-12.
39. Lazarovits J, Sindhwani S, Tavares AJ, Zhang Y, Song F, Audet J, et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS nano. 2019; 13(7):8023-34.
40. Oh E, Liu R, Nel A, Gemill KB, Bilal M, Cohen Y, et al. Meta-analysis of cellular toxicity for cadmium-containing quantum dots. Nature nanotechnology. 2016; 11(5):479-86.
41. Schwarzer A, Talbot SR, Selich A, Morgan M, Schott JW, DittrichBreiholz O, et al. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning. Molecular Therapy. 2021; 29(12):3383-97.
42. Fu X, Cai L, Zeng X, Zou Q. StackCPPred: a stacking and pairwise energy content-based prediction of cell-penetrating peptides and their uptake efficiency. Bioinformatics. 2020; 36(10):3028-34.
43. Damiati SA, Alaofi AL, Dhar P, Alhakamy NA. Novel machine learning application for prediction of membrane insertion potential of cellpenetrating peptides. International journal of pharmaceutics. 2019; 567:118453.
44. A. Kumar, P. K. Gupta, and A. Srivastava, "A review of modern technologies for tackling COVID-19 pandemic," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
45. M. Rojas et al., "Convalescent plasma in Covid-19: Possible mechanisms of action," Autoimmunity Reviews, p. 102554, 2020
46. V. Chamola, V. Hassija, V. Gupta, and M. Guizani, "A Comprehensive Review of the COVID-19 Pandemic and the Role of IoT, Drones, AI, Blockchain, and 5G in Managing its Impact," IEEE Access, vol. 8, pp. 90225-90265, 2020.
47. C. Long et al., "Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?," European journal of radiology, p. 108961, 2020.
48. L. Wynants et al., "Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal," bmj, vol. 369, 2020.
49. A. A. Ardakani, A. R. Kanafi, U. R. Acharya, N. Khadem, and A. Mohammadi, "Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks," Computers in Biology and Medicine, p. 103795, 2020.
50. M. A. Elaziz, K. M. Hosny, A. Salah, M. M. Darwish, S. Lu, and A. T. Sahlol, "New machine learning method for image-based diagnosis of COVID-19," Plos one, vol. 15, no. 6, p. e0235187, 2020.
51. A. Imran et al., "AI4COVID-19: AI enabled preliminary diagnosis for COVID-19 from cough samples via an app," arXiv preprint arXiv: 2004.01275, 2020.
52. G. F. Cooper et al., "An evaluation of machine-learning methods for predicting pneumonia mortality," Artificial intelligence in medicine, vol. 9, no. 2, pp. 107-138, 1997
53. M. Pourhomayoun and M. Shakibi, "Predicting mortality risk in patients with COVID-19 using artificial intelligence to help medical decision-making," medRxiv, 2020
54. S. Thapa, S. Adhikari, and S. Mishra, "Review of Text Summarization in Indian Regional Languages," in 2020 International Conference on Computing Informatics & Networks (ICCIN), 2020: Springer.
55. S. Thapa, S. Adhikari, U. Naseem, P. Singh, G. Bharathy, and M. Prasad, "Detecting Alzheimer's Disease by Exploiting Linguistic Information from Nepali Transcript", in 2020 27th International Conference on Neural Information Processing, 2020: Springer
56. S. Tuli, S. Tuli, R. Tuli, and S. S. Gill, "Predicting the Growth and Trend of COVID-19 Pandemic using Machine Learning and Cloud Computing," Internet of Things, p. 100222, 2020.

JURIHUM : Jurnal Inovasi dan Humaniora
Volume 1, No.1 Juni, 2023
ISSN 3025-7409 (Media Online)
Hal 17-29

57. H. Chen, O. Engkvist, Y. Wang, M. Olivecrona, and T. Blaschke, "The rise of deep learning in drug discovery," Drug discovery today, vol. 23, no. 6, pp. 1241-1250, and 2018
58. N. Bansal, R. Gautam, R. Tiwari, S. Thapa, and A. Singh, "Economic Load Dispatch Using Intelligent Particle Swarm Optimization", in 2020 2nd International Conference on Intelligent Computing, Information and Control Systems (ICICCS 2020), 2020: Springer
59. N. Bansal, S. Thapa, S. Adhikari, A. K. Jha, A. Gaba, and A. Jha, "Novel Exponential Particle Swarm Optimization Technique for Economic Load Dispatch", 2nd International Conference on Inventive Computation and Information Technologies, 2020: Springer.
60. V. Chenthamarakshan et al., "Target-specific and selective drug design for covid-19 using deep generative models," arXiv preprint arXiv: 2004.01215, 2020
61. D. R. Flower, I. K. Macdonald, K. Ramakrishnan, M. N. Davies, and I. A. Doytchinova, "Computer aided selection of candidate vaccine antigens," Immunome research, vol. 6, no. 2, pp. 1-16, 2010
62. E. Ong, H. Wang, M. U. Wong, M. Seetharaman, N. Valdez, and Y. He, "Vaxign-ML: supervised machine learning reverse vaccinology model for improved prediction of bacterial protective antigens," Bioinformatics, vol. 36, no. 10, pp. 3185-3191, 2020.
63. A. Senior, J. Jumper, D. Hassabis, and P. Kohli, "AlphaFold: Using AI for scientific discovery," DeepMind. Recuperado de: https://deepmind. Com/blog/alphafold, 2018
64. J. Jumper, K. Tunyasuvunakool, P. Kohli, D. Hassabis, and A. Team, "Computational predictions of protein structures associated with COVID-19," DeepMind, 2020.
65. A. K. Jha, S. Adhikari, S. Thapa, A. Kumar, A. Kumar, and S. Mishra, "Evaluation of Factors Affecting Compressive Strength of Concrete using Machine Learning" in 2020 Advanced Computing and Communication Technologies for High Performance Applications (ACCTHPA), 2020: IEEE.
66. J. C. M. Serrano, O. Papakyriakopoulos, and S. Hegelich, "NLP - based Feature Extraction for the Detection of COVID-19 Misinformation Videos on YouTube," openreview.net, 2020. [24] S. Thapa, S. Adhikari, A. Ghimire, and A. Aditya, "Feature Selection Based Twin-Support Vector Machine for the diagnosis of Parkinson's Disease", in 2020 8th R10 Humanitarian Technology Conference (R10-HTC), 2020: IEEE
67. R. P. Singh, M. Javaid, A. Haleem, and R. Suman, "Internet of t hings (IoT) applications to fight against COVID-19 pandemic," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020.
68. O. Bestsennyy, G. Gilbert, A. Harris, and J. Rost, "Telehealth: A Quarter-Trillion-Dollar Post-COVID-19 Reality?" McKinsey & Company. Published May, vol. 29, 2020
69. S. Tasnim, M. M. Hossain, and H. Mazumder, "Impact of rumors and misinformation on COVID-19 in social media," Journal of preventive medicine and public health, vol. 53, no. 3, pp. 171-174, 2020.
70. D. Domingo-Fernandez et al., "COVID-19 Knowledge Graph: a computable, multi-modal, cause-and-effect knowledge model of COVID-19 pathophysiology," BioRxiv, 2020.
71. S. Thapa, P. Singh, D. K. Jain, N. Bharill, A. Gupta, and M. Prasad, "Data-Driven Approach based on Feature Selection Technique for Early Diagnosis of Alzheimer's Disease", in 2020 International Joint Conference on Neural Networks (IJCNN), 2020: IEEE.
72. H. Jelodar, Y. Wang, R. Orji, and H. Huang, "Deep sentiment classification and topic discovery on novel coronavirus or covid-19 online discussions: Nlp using lstm recurrent neural network approach," arXiv preprint arXiv: 2004.11695, 2020
73. Z. Yang et al., "Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions," Journal of T horacic Disease, vol. 12, no. 3, p. 165, 2020
74. A. Zhavoronkov et al., "Potential non-covalent SARS-CoV-2 3C-like protease inhibitors designed using generative deep learning approaches and reviewed by human medicinal chemist in virtual reality," ChemRxiv, 2020.